Related Experiment Video
Updated: Feb 10, 2026

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
Published on: January 5, 2024
Prevention of recurrent venous thrombosis and post-thrombotic syndrome
Gianni Belcaro1, Mark Dugall2, Shu Hu2
1Irvine3 Labs, Circulation Sciences and The Nicolaides' Lab, Dipartimento Sc Med OR BIOTEC, CH-PE University, IA-PSS, Pescara, Italy - cardres@abol.it.
Insights
Pycnogenol® significantly reduced recurrent deep venous thrombosis (R-DVT) and post-thrombotic syndrome (PTS) compared to standard management and aspirin. This study highlights Pycnogenol® as a safe and effective option for managing DVT complications.
Area of Science:
- Vascular Medicine
- Pharmacology
- Thrombosis Research
Background:
- Post-thrombotic syndrome (PTS) and recurrent deep venous thrombosis (R-DVT) are significant complications following proximal deep vein thrombosis (DVT).
- Standard management (SM) protocols aim to mitigate these risks, but further therapeutic options are being investigated.
Purpose of the Study:
- To evaluate the efficacy of different antithrombotic agents in preventing PTS and R-DVT after proximal DVT.
- To compare Pycnogenol®, ticlopidine, sulodexide, and aspirin against standard management in a post-anticoagulant setting.
Main Methods:
- A retrospective registry study involving patients who completed anticoagulant therapy for proximal DVT.
- Comparable groups were assigned to standard management (SM), aspirin (100 mg/day), Pycnogenol® (200 mg/day), ticlopidine (250 mg/day), or sulodexide (500 ULS/day).
Main Results:
- Pycnogenol® demonstrated the lowest incidence of R-DVT (5.8%) and PTS (6.5%), significantly outperforming SM and aspirin (P<0.05).
- Aspirin showed a significant reduction in R-DVT and PTS compared to SM (P<0.05).
- Ticlopidine and sulodexide also exhibited significant reductions in R-DVT and/or PTS compared to SM (P<0.05).
Conclusions:
- Pycnogenol® is the most effective and safe agent for reducing R-DVT and particularly PTS.
- Aspirin is effective in reducing PTS and R-DVT for patients who tolerate it.
- Ticlopidine and sulodexide are also effective antithrombotic strategies in this patient population.
Background:
This retrospective registry study evaluated different managements on the development of post-thrombotic syndrome (PTS) and recurrent deep venous thrombosis (R-DVT). The effects of aspirin (100 mg/day), added to the "standard management" (SM) (IUA consensus), were observed in patients after a proximal DVT.
Methods:
The study started after the anticoagulant period. Comparable groups used the mild-antithrombotic agent Pycnogenol® (200 mg/day), ticlopidine (250 mg/day) or sulodexide (500 ULS/day).
Results:
The groups were comparable for sex and age distribution and clinical pictures. In the SM group, 222 patients completed the follow-up (72 months). With SM, the percentage of patients with R-DVT (requiring anticoagulants) was 17.2%; 19.8% of SM patients had a PTS. In the aspirin group (202 subjects), R-DVT was observed in 14.8% of patients; 17.32% had a PTS. The reduction in R-DVT and PTS with aspirin was significant (P<0.05) vs. the SM. There was no tolerability problem in subjects using Pycnogenol® (137 patients); they had a much lower incidence of R-DVT (5.8%) and PTS (6.5%) vs. SM and aspirin (P<0.05). Ticlopidine (121 patients) reduced the incidence of R-DVT (12.4%) and PTS (19.8% of patients) (P<0.05 vs. SM). With sulodexide the incidence of R-DVT was 6.7% (P<0.05 vs. SM); the incidence of PTS was 16.6% (P<0.05 vs. SM). The combined R-DVT+PT syndrome was observed in 14.9% of subjects using SM and in 12.9% of subjects using aspirin (P<0.05 vs. SM), in 3.6% of subjects managed with Pycnogenol® (<0.05% vs. aspirin and all other managements). The incidence was 10.74% with ticlopidine and 6.7% with sulodexide (both significantly lower than SM).
Conclusions:
Interaction between PTS and R-DVT are complex; recurrences cause more PTSs, and a post-thrombotic limb is prone to R-DVT. Aspirin, for patients that can tolerate it, reduces the occurrence of PTS and R-DVT. In addition, ticlopidine and sulodexide are effective. Pycnogenol® is the most effective and safe for R-DVT and particularly PTS. Its full range of anti-thrombotic activity is now under evaluation.
Related Concept Videos
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Return
What is Venous Return?
Venous return refers to the rate at which blood flows back to the heart from the body's peripheral veins. It's an integral part of the circulatory system...
Cancer Prevention
Some...

